BRPI0516464A - formulação farmacêutica, método para a preparação de um produto farmacêutico, e, uso de uma formulação farmacêutica - Google Patents

formulação farmacêutica, método para a preparação de um produto farmacêutico, e, uso de uma formulação farmacêutica

Info

Publication number
BRPI0516464A
BRPI0516464A BRPI0516464-8A BRPI0516464A BRPI0516464A BR PI0516464 A BRPI0516464 A BR PI0516464A BR PI0516464 A BRPI0516464 A BR PI0516464A BR PI0516464 A BRPI0516464 A BR PI0516464A
Authority
BR
Brazil
Prior art keywords
pharmaceutical
pharmaceutical formulation
formulation
preparation
preparing
Prior art date
Application number
BRPI0516464-8A
Other languages
English (en)
Inventor
Petter Berglund
Charlotte Hammelev
Lone Eskildsen
Johanne Madsen
Helle Aalund Olsen
Lone Logstrup Kimer
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35428106&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0516464(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BRPI0516464A publication Critical patent/BRPI0516464A/pt
Publication of BRPI0516464B1 publication Critical patent/BRPI0516464B1/pt
Publication of BRPI0516464B8 publication Critical patent/BRPI0516464B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

FORMULAçãO FARMACêUTICA, METODO PARA A PREPARAçãO DE UM PRODUTO FARMACêUTICO, E, USO DE UMA FORMULAçãO FARMACêUTICA. A invenção provê uma formulação farmacêutica e um método para preparar a formulação.
BRPI0516464A 2004-10-05 2005-10-05 método para a preparação de um produto farmacêutico BRPI0516464B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200401519 2004-10-05
PCT/EP2005/055017 WO2006037789A1 (en) 2004-10-05 2005-10-05 A pharmaceutical formulation comprising crystalline insulin and dissolved insulin

Publications (3)

Publication Number Publication Date
BRPI0516464A true BRPI0516464A (pt) 2008-09-09
BRPI0516464B1 BRPI0516464B1 (pt) 2016-11-08
BRPI0516464B8 BRPI0516464B8 (pt) 2021-05-25

Family

ID=35428106

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516464A BRPI0516464B8 (pt) 2004-10-05 2005-10-05 método para a preparação de um produto farmacêutico

Country Status (19)

Country Link
US (1) US7884181B2 (pt)
EP (4) EP1802329B1 (pt)
JP (1) JP5080259B2 (pt)
KR (1) KR101238184B1 (pt)
CN (2) CN102772788B (pt)
AU (1) AU2005291233B2 (pt)
BR (1) BRPI0516464B8 (pt)
CA (1) CA2581798A1 (pt)
CY (1) CY1124650T1 (pt)
DK (1) DK2918286T3 (pt)
ES (3) ES2774354T3 (pt)
HU (1) HUE048806T2 (pt)
LT (1) LT2918286T (pt)
MX (1) MX2007003897A (pt)
PL (2) PL1802329T3 (pt)
PT (1) PT2918286T (pt)
RU (1) RU2389503C2 (pt)
SI (1) SI2918286T1 (pt)
WO (1) WO2006037789A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008065138A1 (en) * 2006-11-29 2008-06-05 Novo Nordisk A/S Novel insulin crystal and method for preparing the crystal
CN102219851B (zh) * 2011-05-09 2012-05-30 甘李药业有限公司 甘精胰岛素结晶的制备方法
MX2015006997A (es) * 2012-12-26 2015-09-23 Wockhardt Ltd Composicion farmaceutica.
JP6641280B2 (ja) 2014-01-09 2020-02-05 サノフイＳａｎｏｆｉ インスリンアナログおよび／またはインスリン誘導体の安定化された医薬製剤
RU2014120626A (ru) * 2014-05-22 2015-11-27 Владимир Андреевич Сабецкий Инсулинсодержащий препарат пролонгированного действия
CN105535942B (zh) * 2016-01-28 2017-07-28 通化东宝药业股份有限公司 一种赖脯胰岛素硫酸鱼精蛋白制剂的制备方法及其制备的赖脯胰岛素硫酸鱼精蛋白制剂
WO2017163159A1 (en) * 2016-03-21 2017-09-28 Wockhardt Limited Biphasic pharmaceutical composition of insulin human
WO2022268208A1 (zh) * 2021-06-25 2022-12-29 甘李药业股份有限公司 含酰化胰岛素的药物组合物
CN113248591B (zh) * 2021-07-08 2021-09-28 北京惠之衡生物科技有限公司 一种门冬胰岛素结晶工艺
CN113384529B (zh) * 2021-07-08 2021-11-26 北京惠之衡生物科技有限公司 一种门冬胰岛素注射液及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB889769A (en) * 1957-07-18 1962-02-21 Nordisk Insulinlab Slowly acting insulin preparation in crystalline form
DK72793D0 (da) 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US5461031A (en) * 1994-06-16 1995-10-24 Eli Lilly And Company Monomeric insulin analog formulations
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
CA2258099A1 (en) * 1996-06-20 1997-12-24 Novo Nordisk A/S Insulin preparations containing carbohydrates
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
HU228094B1 (en) 1996-06-20 2012-10-29 Novo Nordisk As Insulin preparations containing nacl
US5948751A (en) 1996-06-20 1999-09-07 Novo Nordisk A/S X14-mannitol
AU2002346490A1 (en) * 2001-12-20 2003-07-09 Eli Lilly And Company Insulin molecule having protracted time action
EP1605967A1 (en) * 2003-03-13 2005-12-21 Novo Nordisk A/S Novel nph insulin preparations

Also Published As

Publication number Publication date
CA2581798A1 (en) 2006-04-13
JP5080259B2 (ja) 2012-11-21
CY1124650T1 (el) 2022-03-24
PL1802329T3 (pl) 2015-10-30
EP2926828A1 (en) 2015-10-07
HUE048806T2 (hu) 2020-08-28
AU2005291233B2 (en) 2011-02-03
US7884181B2 (en) 2011-02-08
EP1802329A1 (en) 2007-07-04
PT2918286T (pt) 2020-03-27
PL2918286T3 (pl) 2020-06-29
JP2008515853A (ja) 2008-05-15
WO2006037789A1 (en) 2006-04-13
LT2918286T (lt) 2020-04-10
AU2005291233A1 (en) 2006-04-13
SI2918286T1 (sl) 2020-06-30
ES2779957T3 (es) 2020-08-20
EP3689366A1 (en) 2020-08-05
RU2007111879A (ru) 2008-11-20
CN101035557B (zh) 2012-09-05
US20080171694A1 (en) 2008-07-17
RU2389503C2 (ru) 2010-05-20
CN101035557A (zh) 2007-09-12
EP2926828B1 (en) 2019-12-11
BRPI0516464B1 (pt) 2016-11-08
EP2918286A1 (en) 2015-09-16
CN102772788A (zh) 2012-11-14
MX2007003897A (es) 2007-05-21
EP2918286B1 (en) 2020-03-18
ES2544329T3 (es) 2015-08-28
DK2918286T3 (da) 2020-03-30
KR101238184B1 (ko) 2013-03-04
CN102772788B (zh) 2017-06-06
EP1802329B1 (en) 2015-05-06
BRPI0516464B8 (pt) 2021-05-25
KR20070100874A (ko) 2007-10-12
ES2774354T3 (es) 2020-07-20

Similar Documents

Publication Publication Date Title
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
CL2007003100A1 (es) Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria.
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
UY28342A1 (es) Nuevos compuestos
NO20092611L (no) Krystallinsk faststoff Rasagilin base
BRPI0809366A8 (pt) polipeptídeos interligados
CY1109010T1 (el) γ-ΚΡΥΣΤΑΛΛΙΚΗ ΜΟΡΦΗ ΤΗΣ ΥΔΡΟΧΛΩΡΙΚΗΣ ΙΒΑΒΡΑΔΙΝΗΣ, ΜΕΘΟΔΟΣ ΠΑΡΑΣΚΕΥΗΣ ΤΗΣ ΚΑΙ ΦΑΡΜΑΚΕΥΤΙΚΕΣ ΣΥΝΘΕΣΕΙΣ ΠΟΥ ΤΗΝ ΠΕΡΙΕΧΟΥΝ
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
ITMI20031570A1 (it) Composizione per uso dietetico, farmaceutico o cosmetico
WO2006007448A3 (en) Pharmaceutical co-crystal compositions and related methods of use
CL2004000889A1 (es) COMPUESTOS DERIVADOS DE PIRAZOLO[4,3-d]PIRIMIDINA; COMPUESTOS INTERMEDIARIOS; COMPOSICION FARMACEUTICA; PROCEDIMIENTO DE PREPARACION Y SU USO EN LA PREPARACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA HIPERTENSION.
CR8778A (es) Revestimientos de azucar y metodos para estos
BRPI0512792A (pt) formas cristalinas sólidas de cloridrato de ( - ) - (1r, 2r) - 3 - (3-dimetilamino-1-etil-2-metilpropil) - fenol
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
BRPI0911203A2 (pt) peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo.
NO20070785L (no) Sammensetninger for levering av svaert vannloselige medikamenter.
ECSP088296A (es) Compuestos terapéuticos
NO20054329D0 (no) Adamantanderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som innbefatter slike
BRPI0312649A2 (pt) compostos, composições farmacêuticas contendo os mesmos, e processos de uso para os mesmos.
EP4053155A4 (en) KERATIN BD-4, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
UY30308A1 (es) Moduladores de mglur5 v
CY1124650T1 (el) Φαρμακευτικο παρασκευασμα που περιεχει ινσουλινη σε κρυσταλλικη μορφη καθως και σε διαλυτοποιημενη μορφη
HN2004000109A (es) Nueva difenilazetidinona con propiedades fisiologicas mejoradas, procedimiento para su preparacion, medicamentos que comprenden este compuesto y su uso
UY30307A1 (es) Moduladores de mglur5 vi
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/11/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/10/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2795 DE 30-07-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.